All In Biotech

NDA 208686 · Azurity

Epaned

Enalapril Maleate · Oral

Orphan

Last checked: Nov 19, 2026Latest source record: Jul 28, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2016

Sep 20, 2016

Approved uses

1

Original approval plus efficacy supplements

Registered trials

156

43 Phase 3, 13 recruiting

FAERS reports

19,244

16,050 serious, 2,248 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: FETAL TOXICITY • When pregnancy is detected, discontinue ENALAPRIL MALEATE as soon as possible. [See Warnings and Precautions ( 5.1 )] • Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. [See Warnings and Precautions ( 5.1 )] WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. • When pregnancy is detected, discontinue ENALAPRIL MALEATE as soon as possible ( 5.1 ). • Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus ( 5.1 ).

What it is approved for

From the label in effect Dec 16, 2025.

Enalapril maleate is an angiotensin-converting enzyme inhibitor indicated for: treatment of hypertension in adults and children older than one month, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.1 ). treatment of symptomatic heart failure ( 1.2 ). treatment of asymptomatic left ventricular dysfunction, to decrease the rate of development of overt heart failure and reduce hospitalization for heart failure ( 1.3 ). 1.1 Hypertension Enalapril maleate is indicated for the treatment of hypertension, to lower blood pressure in adults and children older than one month [see Pediatric Use ( 8.4 ) and Clinical Studies ( 14 )]. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it...

Mechanism: Enalapril, after hydrolysis to enalaprilat, inhibits angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. The beneficial effects of enalapril in hypertension and heart failure appear to result primarily from suppression of the renin-angiotensin-aldosterone system. Inhibition of ACE results in decreased plasma angiotensin II, which leads to decreased vasopressor activity and to...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 20, 2016 Original approval · Type 5 - New Formulation or New Manufacturer OrphanLetterReviewLabel
1 products under this application
  • EPANED · ENALAPRIL MALEATE 1MG/ML · SOLUTION, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Enalapril" as an intervention, any sponsor and status, largest first.

All 156 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea1,002
  • nausea989
  • dyspnoea960
  • fatigue849
  • dizziness812
  • drug interaction797
  • drug ineffective730
  • vomiting719
  • asthenia660
  • pain649
  • headache637
  • hypertension637

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004933
2005931
20061,119
20071,006
20081,475
20091,201
20101,597
20112,111
20121,671
2013373
2014458
2015478
2016532
2017552
2018654
2019632
2020578
2021581
2022559
2023548
2024527
2025423
2026304

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Epaned (Enalapril Maleate)

2024 spending

$88K

Beneficiaries

14

63 claims

Per beneficiary

$6,264

$3.97 per unit

View as table
YearSpending
2020$599,784
2021$617,209
2022$279,901
2023$159,539
2024$87,690

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,932 on PubMed

Sponsor: Azurity

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.